Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$179.5MMiss by $22.4M
EPS$0.70Beat by $0.05
Revenue estimate$201.9M
EPS estimate$0.65

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$191.1M
EPS estimate$0.64

Financials

Q3 2025

Income statement

See full
Revenue$179.5M+6.5%
Gross profit$145.2M+12.0%
Operating income$6.4M+105%
Net income$5.4M+104%
EPS (diluted)$0.12+104%

Balance sheet

See full
Cash & equivalents$147.6M-40.0%
Total debt$425.3M+16.3%
Total equity$727.2M-3.0%
Total assets$1.3B-14.7%

Cash flow

See full
Operating cash flow$60.8M+12.8%
CapEx$3.9M-5.4%
Free cash flow$57.0M+14.3%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.16B+66.6%
Enterprise value$1.44B+76.3%
P/S1.6×+0.6×

Profitability

See full
Gross margin79.2%+4.8pp
FCF margin17.3%-10.5pp

Returns & leverage

See full
Debt / equity0.6×+0.1×
Current ratio5.3×+3.0×

Segments

By product

See full
EXPAREL$139.9M+6.0%
ZILRETTA$29.0M+2.0%
iovera°$6.5M+14.3%
Bupivacaine liposome injectable suspension$2.7M+63.8%

By segment

See full
Reportable Segment$179.5M+6.5%

Versus estimates

Revenue

Q1 2026$177.4MBeat by $5.6MQ4 2025$196.9MMiss by $3.5M
Q3 2025$179.5MMiss by $22.4M
Q2 2025$181.1MMiss by $1.3MQ1 2025$168.9MMiss by $18.6MQ4 2024$187.3MBeat by $1.9M

Diluted EPS

Q1 2026$0.60Miss by $0.01Q4 2025$0.57Miss by $0.28
Q3 2025$0.70Beat by $0.05
Q2 2025$0.74Beat by $0.02Q1 2025$0.62Beat by $0.05Q4 2024$0.91Beat by $0.13

Ask the moment Pacira BioSciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Pacira BioSciences, Inc. report Q3 2025 earnings?
Pacira BioSciences, Inc. (PCRX) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Pacira BioSciences, Inc.'s Q3 2025 revenue and EPS?
Pacira BioSciences, Inc. reported revenue of $179.5M and eps of $0.70 for Q3 2025.
Did Pacira BioSciences, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $201.9M by $22.4M. EPS beat the consensus estimate of $0.65 by $0.05.
How did Pacira BioSciences, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.5% from $168.6M a year earlier and eps declined 11.4% from $0.79.
Where can I find Pacira BioSciences, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-050145) and the 10-Q periodic report (0001628280-25-050176) directly on SEC EDGAR. The filing index links above go to sec.gov.